For many people, imagining a juicy burger or a cold beer instantly sparks desire and action. This link between mental imagery and behavior helps us seek food, drink and other rewards needed for survival. When this system goes awry, it can contribute to overeating, substance misuse and addiction.
Researchers have long suspected that vivid mental images of rewarding experiences are tied to compulsive consumption. Since the 1970s, studies have linked intense craving-related imagery with drug abuse and relapse. Yet the precise brain mechanisms connecting thoughts, desire and consumption have remained difficult to pinpoint.
Weight-loss drugs transform addiction research
The rapid rise of GLP-1 agonist drugs such as Ozempic and Wegovy is now offering an unexpected window into this problem. Originally developed to treat type 2 diabetes, these drugs mimic the hormone GLP-1, helping the body release insulin, slow digestion and increase feelings of fullness after eating.
Patients taking GLP-1 agonists began to lose substantial amounts of weight, in some trials approaching results previously seen only with bariatric surgery. This dramatic effect turned them into blockbuster weight-loss medications and sparked intense public, scientific and commercial interest worldwide.
Alongside weight reduction, a quieter pattern emerged from clinical and laboratory data. People on GLP-1 drugs reported drinking less alcohol, finding it easier to stop at one or two drinks or losing interest altogether. Preclinical studies in animals extended this trend to drugs such as cocaine, amphetamines, opioids and nicotine.
These findings suggest GLP-1 agonists are not just curbing appetite but reshaping how the brain processes reward. That has prompted neuroscientists to revisit long-standing models of addiction and search for the precise brain regions where GLP-1 is dampening the drive to consume.
Beyond classic dopamine reward pathways
Traditional neuroscience places the brain’s reward machinery in dopamine-rich areas such as the ventral tegmental area and the nucleus accumbens. These structures are central to reinforcement learning, habit formation and the feeling of reward after eating, drinking or taking drugs.
It would be natural to assume GLP-1 drugs act directly on these classic reward hubs. However, detailed mapping shows these areas contain relatively few GLP-1 receptors, making them unlikely to be the main direct target. That has pushed researchers to look “upstream” in the brain’s circuitry.
Attention has increasingly turned to the lateral septum, a region historically linked to emotional regulation. In the 1950s, experiments showed that damage to this area could trigger intense aggression, a phenomenon known as “septal rage”, while stimulation of the region tended to calm animals.
Modern connectivity analysis has since revealed that the lateral septum is deeply embedded in networks that integrate emotion, memory and motivation. Rather than serving a single function, it appears to act as a hub that relays and reshapes information from multiple brain systems, including those governing reward.
A possible control center for craving
The lateral septum receives much of its primary input from the hippocampus, the brain’s key structure for forming episodic memories. The famous patient Henry Molaison, known as HM, lost his ability to create new long-term memories after surgeons removed most of his hippocampus to treat severe epilepsy.
Within the hippocampus, scientists have identified “place cells”, neurons that fire when we occupy or imagine a specific location. More recent work shows these cells can also encode temporal context, helping us track not only where we are, but when events occur in relation to each other.
The lateral septum appears to inherit this rich “where and when” information and then overlay it with details about reward. Studies have found that neurons in the lateral septum also behave like place cells but respond strongly when an animal encounters or anticipates something rewarding in a particular location.
In effect, the lateral septum seems to answer the question “what is good here?” and send that assessment toward dopamine-producing regions. Many neuroscientists now suspect this region helps generate our conscious thoughts about rewards and calibrates the strength of craving linked to remembered places and experiences.
Crucially, the lateral septum is densely packed with GLP-1 receptors. This anatomical detail aligns with a growing body of experimental evidence, positioning it as a prime candidate for mediating the anti-consumption effects of GLP-1 agonist drugs.
GLP-1 drugs and reduced consumption
Animal experiments have begun to test this hypothesis directly. When researchers activate GLP-1 receptors specifically in the lateral septum of mice, the animals eat less, even when food remains easily available. This suggests local GLP-1 signalling can directly suppress feeding behavior.
Further work this year extended the finding to alcohol. When GLP-1 pathways in the lateral septum were stimulated, rodents voluntarily drank less alcohol, despite having free access. This reduction could not be fully explained by nausea or general malaise, pointing instead to changes in reward processing.
Other labs, including the author’s, have reported that GLP-1 drugs alter the communication patterns of lateral septum neurons. By reducing certain forms of neural activity and connectivity, these medications may effectively quiet the brain chatter that links reward memories with the urge to consume.
Together, these converging strands of evidence support the idea that GLP-1 agonists partially work by dampening the lateral septum’s ability to drive reward-focused thoughts. That could explain why some patients describe feeling that food, alcohol or cigarettes simply seem less compelling or less “worth it”.
New hope for obesity and addiction?
The potential implications are far-reaching. If the lateral septum proves to be a key center for conscious craving, it could open new avenues for treating conditions such as obesity, alcohol use disorder and other substance addictions. GLP-1 drugs might become part of a broader toolkit that targets both metabolism and motivation.
Early clinical data already suggest benefits beyond weight loss. Trials of semaglutide, the active ingredient in Ozempic and Wegovy, have reported reduced binge eating and promising signals in patients with alcohol-related problems, though larger dedicated studies are still under way.
Specialists caution that GLP-1 agonists are not a cure-all. They can cause side effects, require long-term use to maintain benefits and may not be suitable for everyone. Concerns over supply, cost and equitable access have also emerged as demand has surged in many countries.
Neuroscientists emphasize that much remains unknown about how exactly GLP-1 signalling reshapes brain networks over time. Future research will need to clarify whether targeting the lateral septum alone is sufficient, or whether broader systems that integrate stress, habit and self-control must also be addressed.
Still, the discovery that a widely used diabetes and weight-loss medication may reveal a hidden craving hub is reshaping theories of addiction. By tracing how GLP-1 drugs modulate the lateral septum and its connections, scientists hope to design more precise treatments that ease harmful cravings without blunting the joys of everyday life.